Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites

Next Previous
Trial Profile

A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Relacorilant (Primary) ; Itraconazole
  • Indications Cushing syndrome; Prostate cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Corcept Therapeutics

Most Recent Events

  • 23 Mar 2020 Status changed from recruiting to completed.
  • 07 Jun 2019 Planned number of patients changed from 48 to 52.
  • 07 Jun 2019 Planned End Date changed from 31 Jul 2019 to 31 Aug 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top